A longitudinal extending body with oriented fibers comprised of an organic compound, preferably cellulose fibers, with a hydrophilic and hydrophobic polymer having absorbable and non res sorbable qualities in the body, with an internal construction to promote cell growth. The longitudinal body has at least one wall having oriented fiber to include cellulose fiber extending the length of said body. This extending body has a surface that is smooth to the touch for additional processing methods such as machining, compression molding and 3 D printing.

Systems and methods for soft tissue to bone repairs, without knot tying. The soft tissue repair systems include self-cinching constructs with a fixation device, a flexible coupler and an optional shuttle/pull device attached to the flexible strand. An accordion-style weave region is formed by pulling on the shuttle/pull device subsequent to the fixation device being secured into the bone, to allow desired tensioning of soft tissue to be fixated or repaired relative to the bone and secured self-locking of the construct.

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.

Disclosed herein are drug delivery devices that can temporally and spatially deliver biologically active agents. An example drug delivery device includes a microneedle array comprising a plurality of microneedles on a surface of a substrate, each microneedle comprising a core comprising a hydrogel and a layer on a surface of the core. Also disclosed are methods of using the drug delivery device, and methods of making the microneedle array that includes a loading device.

An amnion tissue delivery system for delivering amnion tissue into a location within a patient is described. The location within a patient may be a tube, vessel, lumen, orifice, fistula, aneurysm, or chamber. The amnion tissue delivery system employs a catheter and extendable element, such as a removable stent-like structure, in a configuration such that extension of the extendable section deploys the amnion tissue at the desired location. A method for delivery of amnion tissue within a patient is also described. The method includes placing the catheter within the patient using a minimally invasive, endoluminal and/or extraluminal procedure to position tissue, followed by deploying the extendable element to deliver the amnion tissue at the desired location.

Medical stent designs are disclosed. An example stent includes a tubular scaffold having a proximal end and a distal end. The tubular scaffold includes a first filament extending between the proximal end and the distal end, the first filament including a first biodegradable region positioned adjacent to a second biodegradable region. Further, the first biodegradable region includes a first biodegradable material, the first biodegradable material having a first rate of degradation. The second biodegradable region includes a second biodegradable material, the second biodegradable material having a second rate of degradation, wherein the first rate of degradation is different from the second rate of degradation.

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

A shunt for draining ocular fluid of one embodiment includes a tubular body formed of a mesh material including bioactive glass fiber and collagen, the tubular body including an implantation member and a conduit through the implantation member. The implantation member and the conduit are formed integrally. Other embodiments are also contemplated.

Methods for preparing a PEG composition by co-precipitation of two or more components to produce a substantially homogenous powder. According to some embodiments, the two or more components are at least and partially soluble in a solvent, and at least one component is a functionalized PEG. Contacting the at least two component with the solvent at least partially dissolves the components which are then co-precipitated. The resulting product is substantially homogenous, unlike product made by other methods. The PEG composition may be co-precipitated with additional compounds, such as a colorant like indocyanine green.